Metastatic castration-resistant prostate cancer causes urinary symptoms, fatigue, pain, and more. This article covers the ...

Promptly treating prostate cancer bone metastases with the newest medication ... who use sophisticated imaging technologies such as PET scans, have gotten very good at finding even tiny bone ...

A key gene that fuels the molecular cascade driving prostate cancer bone metastasis progression may open avenues for targeted therapies. Laura is an Assistant Editor for The Scientist. She has a ...

One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

Metastatic prostate cancer can progress in different ways ... evaluations of disease advancement, such as x-rays, bone scans, and other types of imaging. Ready access to cancer cells in blood ...

Those results also were reported in The New England Journal of Medicine. PSMA-PET scans of Michael Rosenblum before treatment (left) show prostate cancer metastases (small dark spots) throughout his ...

If you have metastatic castration-resistant ... People with mCRPC, or any advanced prostate cancer, may experience urinary problems, bone pain, fatigue, and weight loss — or possibly no symptoms ...

The first patient in a phase 2 clinical trial evaluating 67Cu-SAR-bisPSMA for patients with metastatic castration-resistant ...

The Georgetown University Lombardi Comprehensive Cancer Center held a lecture on how certain white blood cells in the immune ...

Bone metastases are cancers that have spread (metastasized) from other tissues in the body through the blood or lymphatic systems to the bone marrow. Bone metastases form the main type of bone ...

Medically reviewed by Jamin Brahmbhatt, MD The treatment of metastatic castration-resistant prostate cancer (mCRPC) involves ...